Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study

NCT04592445 is registered in ClinicalTrials.gov with Axon Therapies, Inc. as lead sponsor.

NCT NCT04592445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study
Lead sponsor
Axon Therapies, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
December 18, 2020
Completion date
August 10, 2029
Enrollment
150 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction (hfpef